Antwerp, Belgium, August 6, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage
biopharmaceutical company focused on fibro-inflammation, today reported financial results for the half year period ended
June 30, 2026, and confirmed its outlook for the second half of 2026.

• Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study
  design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic
  Passability
• Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in
  FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming
  Months
• On Track to Initiate NOV-ERA Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in with AGMB-447 in
  IPF in Second Half of 2026
• Cash and Cash Investments at June 30, 2026 of €252 Million, including $208 Million in Gross Proceeds from Initial
  Public Offering (IPO), Expected to Support Cash Runway into First Half of 2029

Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).

• Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA
  Phase 2b study design, including novel primary endpoint of endoscopic passability
• Study initiation on track, with first participants expected to be dosed in the second half of 2026

Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.

All items on the agenda were approved, including:

• Approval of the statutory financial statements for the financial year ended December 31, 2025.
• Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
• Reappointment of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.
• Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors for a term of four years.

The voting result and all documents relating to the shareholders’ meeting are available on the Agomab investor relations website at https://ir.agomab.com/governance/shareholder-meetings.